Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves First Artificial Pancreas Medical Device For Type 1 Diabetes

XTALKS VITALS NEWS

Medical Device

The device – Medtronic’s MiniMed 670G – is a hybrid closed loop system approved for use in patients over the age of 14.

Tweetables from this article:

Tweet: Medtronic’s SmartGuard HCL algorithm automates #glucosemonitoring and insulin dosing activities http://ctt.ec/83XeE+ Medtronic’s SmartGuard HCL algorithm automates glucose monitoring and insulin dosing activities.

Share this!

September 30, 2016 | by Sarah Hand, M.Sc.

This week the US Food and Drug Administration (FDA) approved the first artificial pancreas device, designed to automatically monitor glucose levels and administer insulin to patients with type 1 diabetes. The device – Medtronic’s MiniMed 670G – is a hybrid closed loop system approved for use in patients over the age of 14.

Patients with type 1 diabetes lack the ability to produce insulin in response to changing blood glucose levels. While the pancreas normally maintains a continuous level of insulin, those with type 1 diabetes often lack this basal level of the hormone in the blood.

“The FDA is dedicated to making technologies available that can help improve the quality of life for those with chronic diseases – especially those that require day-to-day maintenance and ongoing attention,” said Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health. “This first-of-its-kind technology can provide people with type 1 diabetes greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin.”



Comprised of a sensor which measures glucose levels under the skin, an insulin pump and an insulin infusion patch, the artificial pancreas adjusts insulin levels without the need for user input. The MiniMed measures glucose levels at five minute intervals, and only requires patients to manually adjust insulin doses after consuming a carbohydrate meal.

The medical device uses Medtronic’s SmartGuard HCL algorithm to automate glucose monitoring and insulin dosing activities. A customizable system, the MiniMed’s automation level can be changed based on physician and patient needs.

“With SmartGuard HCL, the ability to automate basal insulin dosing 24 hours a day is a much-anticipated advancement in the diabetes community for the profound impact it may have on managing diabetes - particularly for minimizing glucose variability and maximizing time in the target range,” said Dr. Richard M. Bergenstal, principal investigator of the pivotal study and executive director of the Park Nicollet International Diabetes Center in Minneapolis. “The data from the pivotal trial were compelling and I am confident that this therapy will be well-received by both the clinical and patient community.”

Approximately five percent of the diabetic community has type 1 diabetes, according to the US Centers for Disease Control and Prevention (CDC). Traditional management of the disease is very intensive, with patients needing to check their glucose levels consistently throughout the day, and self-administer insulin in order to avoid hyperglycemia.

“The FDA approval of the world's first hybrid closed loop system is a culmination of many years of hard work and close collaboration with the clinical and patient communities to generate the body of evidence needed to advance this technology for those living with diabetes,” said Dr. Francine Kaufman, chief medical officer of the Diabetes Group at Medtronic. “We appreciate the unprecedented speed by which the agency approved our PMA submission to help bring this advanced insulin pump therapy so quickly to U.S. patients living with this challenging disease. We are committed to preparing for commercial launch as quickly as possible while ensuring we provide the most successful rollout of this novel therapy.”


Keywords: FDA, Medical Device, Type 1 Diabetes


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.